Sofinnova Partners closes oversubscribed €82 million Sofinnova MD Start IV fund to create the next generation of medtech companies
The new fund extends Sofinnova’s 20-year track record of company creation with capacity to launch six to eight new ventures across Europe and the US
PARIS, France – September 28, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova MD Start IV at €82 million. The fund, which was oversubscribed, will help expand Sofinnova’s medtech company-creation strategy across Europe and the US with greater capacity to launch new ventures and support them through key stages of development.
